ULCAMED 120mg film-coated tablets medication leaflet

A02BX05 • bismuth oxide • Alimentary tract and metabolism | Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) | Other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)

Tripotassium dicitratobismuthate, also known as bismuth subcitrate expressed as bismuth oxide, is a compound used in the treatment of gastrointestinal conditions, particularly gastric and duodenal ulcers, gastritis, and Helicobacter pylori infections. It is a medication with gastroprotective, antimicrobial, and anti-inflammatory properties, commonly used in H. pylori eradication therapies.

This compound works by forming a protective layer over the gastric mucosa, shielding it from the effects of gastric acid and digestive enzymes. It also has a direct antimicrobial effect against H. pylori, helping to reduce inflammation and promote ulcer healing. Additionally, it stimulates mucosal regeneration, accelerating the healing process.

Although effective, the use of tripotassium dicitratobismuthate requires caution. It may cause side effects such as nausea, constipation, or black stools (a harmless effect caused by bismuth). Prolonged use or high doses can lead to bismuth accumulation in the body, potentially causing toxicity (bismuth encephalopathy), although this is extremely rare.

This medication is used as directed by a doctor, usually in combination with antibiotics and proton pump inhibitors (PPIs) for H. pylori eradication. It is important for patients to follow the prescribed dosage and avoid concurrent use with other bismuth-containing medications. If severe side effects or persistent symptoms occur, medical advice should be sought.